Tags

Type your tag names separated by a space and hit enter

The endocannabinoid system as a novel approach for managing obesity.
J Am Osteopath Assoc. 2007 Apr; 107(4 Suppl 2):S12-20.JA

Abstract

The recent discovery of the endocannabinoid system has led to the development of promising treatments for patients with obesity and associated cardiometabolic risk factors. Basic research has demonstrated that the endocannabinoid system plays an integral role in the regulation of food intake, metabolism, and storage. Research with the endocannabinoid receptor antagonist rimonabant has demonstrated statistically significant improvements in body weight, fasting insulin levels, glucose tolerance, high-density lipoprotein cholesterol levels, serum triglyceride levels, and waist circumference, compared with placebo. Rimonabant has also produced statistically significant improvements in inflammatory markers. Research with rimonabant has demonstrated sustained efficacy for as long as 2 years when used in conjunction with a reduced-calorie diet and moderate physical activity. Rimonabant is the first cannabinoid receptor 1 antagonist to be marketed in Europe and the first to file an New Drug Application in the United States. It may provide a novel therapeutic strategy for the treatment of patients with obesity and associated cardiometabolic risk factors.

Authors+Show Affiliations

Midwestern University/Arizona College of Osteopathic Medicine in Glendale, USA. jlillo3@cox.net

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

17784530

Citation

Lillo, Joseph L.. "The Endocannabinoid System as a Novel Approach for Managing Obesity." The Journal of the American Osteopathic Association, vol. 107, no. 4 Suppl 2, 2007, pp. S12-20.
Lillo JL. The endocannabinoid system as a novel approach for managing obesity. J Am Osteopath Assoc. 2007;107(4 Suppl 2):S12-20.
Lillo, J. L. (2007). The endocannabinoid system as a novel approach for managing obesity. The Journal of the American Osteopathic Association, 107(4 Suppl 2), S12-20.
Lillo JL. The Endocannabinoid System as a Novel Approach for Managing Obesity. J Am Osteopath Assoc. 2007;107(4 Suppl 2):S12-20. PubMed PMID: 17784530.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The endocannabinoid system as a novel approach for managing obesity. A1 - Lillo,Joseph L, PY - 2007/9/6/pubmed PY - 2007/10/24/medline PY - 2007/9/6/entrez SP - S12 EP - 20 JF - The Journal of the American Osteopathic Association JO - J Am Osteopath Assoc VL - 107 IS - 4 Suppl 2 N2 - The recent discovery of the endocannabinoid system has led to the development of promising treatments for patients with obesity and associated cardiometabolic risk factors. Basic research has demonstrated that the endocannabinoid system plays an integral role in the regulation of food intake, metabolism, and storage. Research with the endocannabinoid receptor antagonist rimonabant has demonstrated statistically significant improvements in body weight, fasting insulin levels, glucose tolerance, high-density lipoprotein cholesterol levels, serum triglyceride levels, and waist circumference, compared with placebo. Rimonabant has also produced statistically significant improvements in inflammatory markers. Research with rimonabant has demonstrated sustained efficacy for as long as 2 years when used in conjunction with a reduced-calorie diet and moderate physical activity. Rimonabant is the first cannabinoid receptor 1 antagonist to be marketed in Europe and the first to file an New Drug Application in the United States. It may provide a novel therapeutic strategy for the treatment of patients with obesity and associated cardiometabolic risk factors. SN - 0098-6151 UR - https://www.unboundmedicine.com/medline/citation/17784530/The_endocannabinoid_system_as_a_novel_approach_for_managing_obesity_ L2 - http://jaoa.org/article.aspx?volume=107&page=S12 DB - PRIME DP - Unbound Medicine ER -